Results 61 to 70 of about 6,565 (223)

Administration of Supplemental L-Tyrosine with Phenelzine: A Clinical Literature Review [Expression of Concern]

Clinical Pharmacology: Advances and Applications, 2020
Hinz M, Stein A, Cole T, Ryan P. Clin Pharmacol Adv Appl. 2014;6:107– 110. The Editor-in-Chief and Publisher of Clinical Pharmacology: Advances and Applications wish to issue an Expression of Concern for the published article ...
Hinz M, Stein A, Cole T, Ryan P
doaj  

Phenelzine: An old drug that may hold clues to the development of new neuroprotective agents

Psychiatry and Clinical Psychopharmacology, 2021
The monoamine oxidase (MAO)-inhibiting antidepressant phenelzine (PLZ) is also used in the treatment of anxiety disorders such as panic disorder and social anxiety disorder and has been shown to have neuroprotective actions in an animal model of ...
Erin M. MacKenzie, Mee-Sook Song, Serdar Dursun, Sara Tomlinson, Kathryn G. Todd, Glen B. Baker   +5 more
doaj  

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes

British Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Stephanie Annett, Detlev Boison, Kathryn Elisa Burns, Carmen Dessauer, Jürg Gertsch, Nuala Ann Helsby, Angelo A. Izzo, Rennolds Ostrom, Ester Pagano, Andreas Papapetropoulos, Nigel J. Pyne, Susan Pyne, Tracy Robson, Roland Seifert, Johannes‐Peter Stasch, Csaba Szabo, Mario van der Stelt, Albert van der Vliet, Val Watts, Szu Shen Wong   +31 more
wiley   +1 more source

Epigenetic therapy in urologic cancers: an update on clinical trials [PDF]

, 2016
Epigenetic dysregulation is one of many factors that contribute to cancer development and progression. Numerous epigenetic alterations have been identified in urologic cancers including histone modifications, DNA methylation changes, and microRNA ...
Agarwal, Aggarwal, Alon, Anant, Arbor, Bassi, Bastian, Bates, Baylin, Benevolenskaya, Bologna, Borden, Burris, Cairns, Cairns, Carducci, Carducci, Catto, Chi, Clark, Clark, Cole, Croce, Croce, Dahiya, Dahiya, de Balincourt, de Bono, de Bono, Domingos, Dorr, Ehtejab, Eisen, Eisenberger, Eisenberger, Eisenhauer, Eisenhauer, Ekström, Ellinger, Ferrari, Festuccia, Fuessel, Fuessel, Gleave, Grant, Gregory, Griffiths, Han, Harland, Heinrich, Helin, Helin, Hennenlotter, Hsiao, Huang, Hussain, Investigators, Investigators, Issa, Jemal, Jeronimo, Jones, Kiltie, Kim, Kim, Kouzarides, Kouzarides, Kristiansen, Kristiansen, Liang, Liang, Lin, Lyko, Maitland, Manoharan, Marks, Martel, Martell, Meeran, Muller, Nelson, Ochiya, Ogawa, Osman, Pectasides, Pili, Pili, Pompidou, Ren, Rudek, Sartor, Sawyers, Schellhammer, Scher, Sediqe, Shariat, Shi, Sidransky, Sukumar, Tewari, Tolcher, Tolcher, Torti, Verma, Verma, Visakorpi, Von Hoff, Von Ruecker, Wilding, Winquist, Wu, Ørntoft   +111 more
core   +1 more source

The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies

Obesity Reviews, Volume 26, Issue 12, December 2025.
ABSTRACT Obesity is a chronic metabolic disease characterized by disturbances in energy homeostasis, leading to excessive fat accumulation. The pathogenesis of the disease is shaped by a complex interplay of genetic, epigenetic, biological, psychological, and environmental factors.
Gašper Tonin, Stjepan Eržen, Zala Mlinarič, Dubravka Jurišić Eržen, Simon Horvat, Tanja Kunej, Jasna Klen   +6 more
wiley   +1 more source

The effect of placebo and neurophysiological involvements [PDF]

, 2004
Placebo and placebo effect are important issues related to the drug therapy for clinical and scientific meanings. The rates of placebo may get as many as 50% for analgesic drugs in headache. The high answer to placebo brings questions on pathophysiology
Galli, Federica, Guidetti, Vincenzo, Riccio, B.   +2 more
core   +1 more source

REVERSİBLE MAO İNHİBİTORS İN THE TREATMENT OF PANİC DISORDERS

Psychiatry and Clinical Psychopharmacology, 2021
Members of three classes of drugs have been shown to have efficacy-tricyclic antidepressants,monoamine oxidase inhibitors and benzodiazepins. Imipramine and clomipramine have been the tricyclic antidepressants most extensively studied.
Nesrin DİLBAZ, Giray ARIHAN, Verda BİTLİS, Demir TAN   +3 more
doaj  

Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin

Journal of Pharmacy & Pharmaceutical Sciences, 2008
PURPOSE. To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG ...
Kathryn G. Todd, Glen B. Baker
doaj   +1 more source

Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency

Journal of Inherited Metabolic Disease, Volume 48, Issue 6, November 2025.
ABSTRACT Tyrosine hydroxylase (TH) catalyses the rate‐limiting step in dopamine biosynthesis. Autosomal recessive tyrosine hydroxylase deficiency (THD) leads to clinical phenotypes reflecting the deficiency of dopamine, norepinephrine, or epinephrine in the central nervous system (CNS), presenting along a continuous spectrum from mild to severe forms ...
Mariya Sigatullina Bondarenko, Oya Kuseyri Hübschmann, Jan Kulhánek, Roser Pons, Toni S. Pearson, Kathrin Jeltsch, Ivana Badnjarevic, Tessa Wassenberg, Gabriella Horvath, Galina Stevanovic, Manju A. Kurian, Elisenda Cortès‐Saladelafont, Agathe Roubertie, Vincenzo Leuzzi, Mariarita Bertoldi, Mario Mastrangelo, Birgit Assmann, THD Guidelines Working Group, Ines Denzler, Clarisa Maxit, Natalia Alexandra Julia‐Palacios, Shekeeb Mohammad, Helly Goez, Wai‐Ian Yeung, Tomáš Honzík, Ivana Kavecan, Alba Tristán‐Noguero, Alberto Burlina, Daniela Gueraldi, Sushil Bandodkar, Willemsen Michel, Francesco Porta, Sheila Wong, Filippo Manti, Reem Alkhater, Chris Mühlhausen, Alice Kuster, Dimitrios Zafeiriou, Paulo Sgobbi, Wladimir Bocca Vieira de Rezende Pinto, Angeles Garcia‐Cazorla, Thomas Opladen   +41 more
wiley   +1 more source

Lithium Augmentation in Treatment‐Resistant Depression: A Qualitative Review of the Literature

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 10, Page 688-701, October 2025.
ABSTRACT Depression is the leading cause of disability worldwide, affecting people of all ages. Both pharmacological and non‐pharmacological therapies are available for its treatment. However, some patients do not respond to first‐line pharmacological interventions, referred to as treatment‐resistant depression (TRD).
Angela Acero‐González, Yahira Guzman, Nadia Juliana Proaños, Rosa‐Helena Bustos, María Aconcha, Ivan Guerrero, Laura Alejandra Martinez, Michael Berk, Seetal Dodd   +8 more
wiley   +1 more source